Radiation Therapy: External Beam and Brachytherapy

Radiation therapy uses ionizing radiation to damage the DNA of cancer cells, impairing their ability to divide and grow. This page covers the two primary delivery categories — external beam radiation therapy (EBRT) and brachytherapy — including their mechanisms, clinical applications, regulatory oversight, and the factors that guide treatment selection. Understanding these modalities matters because radiation therapy is involved in the treatment of roughly 50 percent of all cancer patients at some point during their disease course, according to the American Society for Radiation Oncology (ASTRO).

Definition and scope

Radiation therapy encompasses any treatment that delivers ionizing radiation — in the form of photons, electrons, protons, or neutrons — to a defined anatomical target with the intent of eliminating malignant cells or controlling tumor growth. The field is regulated and quality-managed under frameworks set by organizations including the Nuclear Regulatory Commission (NRC) for radioactive material licensing and the American College of Radiology (ACR) for practice standards. Radiation oncology as a clinical subspecialty requires distinct residency training — detailed within the radiation oncology residency pathway.

The two primary classifications are:

Both categories fall under broader regulatory context for oncology requirements governing treatment planning, equipment calibration, and patient safety records.

How it works

External Beam Radiation Therapy

EBRT machines — most commonly linear accelerators (linacs) — generate high-energy X-ray beams by accelerating electrons into a target material. The beam is shaped and modulated to conform to the three-dimensional geometry of the tumor. Key technical variants include:

  1. 3D Conformal Radiation Therapy (3D-CRT): Beams are shaped to match tumor contours using CT-based planning; a foundational technique still used for straightforward anatomical sites.
  2. Intensity-Modulated Radiation Therapy (IMRT): The beam is divided into hundreds of small segments, each with independently controlled intensity, allowing dose sculpting around adjacent organs at risk.
  3. Stereotactic Radiosurgery (SRS) / Stereotactic Body Radiation Therapy (SBRT): Highly focused beams deliver ablative doses in 1–5 fractions rather than 25–45 standard fractions. The ACR-ASTRO Practice Parameter for SBRT outlines credentialing and safety requirements for these high-dose approaches.
  4. Proton Therapy: Uses protons rather than photons; deposits the majority of dose at a defined depth (the Bragg peak), reducing exit dose to normal tissue. The National Cancer Institute (NCI) describes its dosimetric advantage in pediatric and centrally located tumors.

Radiation dose is measured in Gray (Gy), where 1 Gy equals 1 joule of energy absorbed per kilogram of tissue. Typical curative EBRT courses for solid tumors deliver total doses ranging from 45 Gy to over 80 Gy, depending on histology and site.

Brachytherapy

In brachytherapy, sealed radioactive sources — most commonly Iridium-192 (Ir-192), Iodine-125 (I-125), or Palladium-103 (Pd-103) — are positioned within or adjacent to the target volume. Delivery is classified by dose rate:

The NRC regulates brachytherapy source possession and use under 10 CFR Part 35, which specifies written directive requirements, physicist oversight, and source accountability procedures.

Common scenarios

Radiation therapy — in one or both forms — appears across a wide range of cancer types covered in depth on this oncology reference site:

Decision boundaries

Selection between EBRT and brachytherapy — or a combination — depends on intersecting clinical, anatomical, and logistical factors:

Factor Favors EBRT Favors Brachytherapy
Tumor accessibility Deep-seated with clear margins Adjacent to natural cavity (cervix, prostate, bronchus)
Dose homogeneity need Large irregular volumes Small, well-defined target
Patient mobility/comorbidity Ambulatory, tolerates daily visits Procedure tolerability required
Reirradiation context Limited prior dose Focal dose escalation possible
Institutional resources Widely available Requires implant expertise and physicist

The managing side effects landscape differs meaningfully between modalities: brachytherapy's dose falloff is steep (inverse-square law over millimeters), reducing integral dose to adjacent structures compared with EBRT. However, brachytherapy carries procedural risks including infection and bleeding at implant sites, whereas EBRT carries risks tied to cumulative dose in transit tissue.

Radiation oncologists follow tumor control probability (TCP) and normal tissue complication probability (NTCP) modeling frameworks when optimizing dose prescriptions. The Radiation Therapy Oncology Group (RTOG) — now operating under NRG Oncology — has defined protocol-based dose constraints for organs at risk across dozens of disease sites through its cooperative group trials.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)